



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bonnie M. Davis.

Serial No.: 10/099,858

Group Art Unit. 1617

Filed: March 14, 2002

Examiner: Shahnam Sharareh

For: USE OF MODULATORS OF NICOTINIC RECEPTORS FOR TREATMENT OF COGNITIVE DYSFUNCTION

Attorney Docket No.: U 013913-4

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

DO NOT
ENTER
CCL
2/6/06

RESPONSE TO FINAL REJECTION OF APRIL 8, 2005

This is in reply to the office action of April 87, 2005 the second rejection of the claims). A notice of appeal was filed on October 11, 2005. A petition for a one month extension of term and a check for \$60.00 is submitted herewith.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks commence on page 8.

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service the date shown with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents P.O. Box 1450, Alexandria VA 22313-1450.

Date: January 10, 2006

John Richards
(Type/print name of person mailing paper)

(Signature of person mailing paper)

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

IN THE CLAIMS

Claim 1 (Currently amended). A method for treating the effects of low LDL-cholesterol values in the brain on cognitive performance or other central nervous system functions of a patient, other than one diagnosed as suffering from Alzheimer's disease, by modulating nicotinic receptors, said method comprising determining the LDL-cholesterol value for such patient and administering an effective amount of a nicotinic allosteric potentiator an acetylcholinesterase inhibitor, nicotine, a nicotinic agonist or a mixture thereof to a patient other than one diagnosed as suffering from Alzheimer's Disease who has been determined to have an a serum-LDL-cholesterol level of below 109 mg/dl.

Claim 2 (canceled).

Claim 3 (Previously Presented). A method as claimed in claim 1 wherein said low cholesterol values are the result of treatment with HMG-CoA reductase inhibitors.

Claim 4 (Previously Presented). A method as claimed in claim 1 wherein said modulation of nicotinic receptors is effected by administering an effective amount of a galanthamine or lycoramine analog to a patient in need of such modulation.

Claim 5 (Withdrawn). A method as claimed in claim 2 wherein said modulation of nicotinic receptors is effected by administering an effective amount of a galanthamine or lycoramine analog to a patient in need of such modulation.

Claim 6 (Withdrawn). A method as claimed in claim 3 wherein said modulation of nicotinic receptors is effected by administering an effective amount of a galanthamine or lycoramine analog to a patient in need of such modulation.